Jaguar Health Extends Convertible Notes Maturity Date to January 2026

Jaguar Health, Inc. (NASDAQ:JAGX) has announced an extension of the maturity date for $2.57 million in convertible promissory notes. Initially set for June 30, 2025, the new maturity date is January 30, 2026. This extension is part of a $3.448 million bridge financing closed in March 2025. Notably, five investors have already converted $0.866 million of this financing into company equity.

Lisa Conte, Jaguar's Founder and CEO, expressed satisfaction with the extension, noting the support it provides in pursuing corporate partnerships. These efforts aim to secure non-dilutive funding for Jaguar's three key development programs involving their plant-based medicine, crofelemer. This includes therapies for intestinal failure, cancer therapy-related diarrhea, and further access for Canalevia® for dogs.